<DOC>
	<DOCNO>NCT02325557</DOCNO>
	<brief_summary>A Phase 1/2 multicenter , dose determining , open-label study ADXS31-142 monotherapy combination ADXS31-142 Pembrolizumab ( MK-3475 ) patient metastatic castration-resistant prostate cancer . Part A dose-determining ADXS31-142 monotherapy . Part B dose-determining ADXS31-142 Pembrolizumad ( MK-3475 ) combination . Part B expansion treat additional patient recommend dose Part B .</brief_summary>
	<brief_title>ADXS31-142 Alone Combination With Pembrolizumab ( MK-3475 ) Patients With Prostate Cancer - KEYNOTE-046</brief_title>
	<detailed_description>Part A study open-label , Phase 1 , multicenter , non-randomized , dose-determining trial ADX31-142 monotherapy subject metastatic castration-resistant prostate cancer ( mCRPC ) . The dose determine phase intend select recommend Phase 2 dose ( RP2D ) Part B . Part B study open-label , Phase 1-2 , multicenter , non-randomized dose-determining trial ADXS31-142 combination pembrolizumab ( MK-3475 ) subject mCRPC . Part B consist dose-determination phase follow expansion cohort phase . The dose-determining phase intend select RP2D combination . Dose escalation/de-escalation study explore apply mTPI design .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Be willing able provide write informed consent trial . 2 . Be 18 year age old day signing inform consent . 3 . Have progressive metastatic castration resistant prostate cancer , androgen deprivation therapy , base least one follow criterion : 1 . PSA progression define 25 % increase baseline value increase absolute value least 2 ng/mL confirm another PSA level minimum 1 week interval minimum PSA 2 ng/ml . 2 . Progression bidimensionally measurable soft tissue ( nodal metastasis ) assess within 1 month prior registration CT scan MRI abdomen pelvis . 3 . Progression bone disease ( evaluable disease ) ( new bone lesion ( ) ) bone scan . 4 . Has discontinue antiandrogens ( bicalutamide , nilutamide ) &gt; 6 week enzalutamide &gt; 4 week prior Day 1 trial treatment 5 . Have performance status 0 1 ECOG Performance Scale . 1 . Received 3 prior systemic treatment regimen chemotherapy , hormonal , immunotherapy metastatic setting receive 1 prior chemotherapeutic regimen metastatic set 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior Day 1 trial treatment . The use physiologic dos corticosteroid may approve consultation Sponsor . 3 . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤Grade 1 baseline ) adverse event due agent administer 4 week earlier . 4 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤Grade 1 baseline ) adverse event due previously administer agent . 5 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent patient previously participate Merck MK3475 clinical trial . 6 . Has contraindication administration ampicillin trimethoprim/ sulfamethoxazole . 7 . Has implant medical device ( ) pose high risk colonization and/or easily remove ( e.g. , prosthetic joint , artificial heart valve , pacemaker , orthopedic screw ( ) , metal plate ( ) , bone graft ( ) , exogenous implant ( ) ) . NOTE : More common device prosthetics include arterial venous stent , dental breast implant , venous access device ( e.g. , PortaCath Mediport ) permit . Sponsor must contact prior consent subject device and/or implant .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>